Virtual screening of anticancer activity of chalcones and pyrazolines as potential EGFR, VEGFR, and cytochrome P450 inhibitors

Author:

Wiraswati Hesti LinaORCID,Bashari M. Hasan,Alfarafisa Nayla MajedaORCID,Ma’ruf Ilma FauziahORCID,Sholikhah Eti NurweningORCID,Wahyuningsih Tutik DwiORCID,Satriyo Pamungkas BagusORCID,Mustofa MustofaORCID,Satria DennyORCID,Damayanti EmaORCID

Abstract

Context: Metastatic breast cancer is still categorized as an incurable disease because all available therapies are palliative treatments to relieve symptoms and increase life expectancy. Our previous study showed that N-pyrazoline-derived compounds have the potential as an antiproliferative drug in cervical cancer cells line. Therefore, virtual screening is conducted in this study to predict the anticancer potential of several molecules (chalcone and pyrazoline derivatives) against breast cancer cells before in vitro testing. Aims: To screen potential anticancer compounds of chalcone and pyrazoline derivatives through in silico approach. Methods: In this study were carried out multiple virtual screening steps to predict drug-likeness, pharmacokinetic, toxicity, and interactions between drug candidates and receptors involved cell in proliferation (EGFR, PDB.id 7LGS), angiogenesis (VEGFR1, PDB.id 3HNG; VEGFR2, PDB.id 4AG8), and oxidative stress (cytochrome P450, PDB.id 3UA1). Results: Results revealed that pyrazolines A, A1, A2, B, C2, D, and M could potentially be anticancer agents since the molecules qualify Lipinski’s rule, are predicted to have good pharmacokinetics, are indicated as harmless, and exhibit the best binding affinity based on molecular docking analysis. Conclusions: The EGFR appears to be the main pathway targeted by pyrazoline derivates. Meanwhile, the ligand will go through the VEGFR1, VEGFR2, or P450 pathways when it successfully overcomes the binding obstacle. In addition, pyrazolines A, A1, A2, B, C2, D, and M need to be synthesized and evaluated the in vitro and in vivo anticancer activity.

Publisher

Garval Editorial Ltda.

Subject

Drug Discovery,Pharmaceutical Science,Pharmacology,Pharmacy,Complementary and alternative medicine

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3